Polar Asset Management Partners Inc. Acquires 101,872 Shares of NKGen Biotech, Inc. (NYSE:NKGN)

Polar Asset Management Partners Inc. increased its holdings in shares of NKGen Biotech, Inc. (NYSE:NKGN) by 9.4% in the third quarter, HoldingsChannel reports. The institutional investor owned 1,181,872 shares of the company’s stock after purchasing an additional 101,872 shares during the quarter. Polar Asset Management Partners Inc.’s holdings in NKGen Biotech were worth $447,000 at the end of the most recent quarter.

Separately, Sequoia Financial Advisors LLC increased its holdings in shares of NKGen Biotech by 273.0% in the third quarter. Sequoia Financial Advisors LLC now owns 69,000 shares of the company’s stock worth $26,000 after acquiring an additional 50,500 shares in the last quarter. 76.17% of the stock is currently owned by institutional investors.

NKGen Biotech Stock Performance

Shares of NKGN opened at $0.44 on Friday. The firm’s 50 day moving average price is $0.35 and its two-hundred day moving average price is $0.81. NKGen Biotech, Inc. has a twelve month low of $0.20 and a twelve month high of $4.06. The firm has a market cap of $15.50 million, a P/E ratio of -0.09 and a beta of 0.77.

NKGen Biotech (NYSE:NKGN) last released its quarterly earnings results on Thursday, September 12th. The company reported ($0.67) earnings per share (EPS) for the quarter.

NKGen Biotech Profile

NKGen Biotech, Inc operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials.